Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient’s with Dyslipidemia

Abstract

In the study, it is aimed to research the likely role of visfatin in hyperthyroid and subclinical hyperthyroid status related to dislipidemia, after determining the visfatin and PON-1 levels thirty healthy individuals were enrolled in this study as control group and thirty hyperthyroidism patient's with dyslipidemia they were treated with. The subjects aged ranged (30-50) years and with BMI (25-29) kg/m 2 . Serum was used in determination of lipid profile total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL), thyroid threonine (T3) and thyroxin (T4), thyroid stimulating hormone (TSH), visfatin and paraoxonase-1 (PON-1). The results showed significant increase in T3, T4, TC, TG, LDL and VLDL in patient group when comparing to control group. While significant decrease was found in TSH and HDL in patient group when comparing to control group. The results also represented significant increase in visfatin levels in patient group comparing to control group. While there are significant reducation in PON-1 levels in patient group comparing to control group. The conclusion could be drown from this study that visfatin and PON-1 effected hyperthyroidism patient's with dyslipidemia All the patients in hyperthyroid group were heterozygotes for Familial Hypercholesterolemia is a disorder that is passed down through families. It causes LDL (bad) cholesterol level to be very high. The condition begins at birth and can cause heart attacks at an early age.

Adipokines/cytokines and disturbances in lipid metabolism

“…Считается, что уровень висфатина увеличивается у людей с ожирением и может иметь потенциальную связь с дислипидемией [50]. Установлено, что повышение содержания висфатина тесно связано с ожирением и дислипидемией у крыс [51]. Тем не менее у людей не обнаружено статистически значимого различия содержания адипокина у лиц без ожирения/избыточного веса и пациентов с ожирением [52].…”